XXXX incidence in Europe: evidence of some deceleration in the increasing trends.

@entity5 @entity1 @entity1355 @entity2615
OBJECTIVE: To summarize the geographical and temporal variations in incidence of @entity2615 in Europe, using the extensive data available from European general cancer registries, and consider these in light of recent trends in @entity1355 extraction, use and import in European countries. MATERIAL AND METHODS: The data were extracted from the European @entity5 Incidence and Mortality database (EUROCIM). The inclusion criteria was acceptance in Volume VII of @entity5 Incidence in Five Continents. Truncated age-standardized rates per 100,000 for the ages 40-74 were used to summarise recent geographical variations. Standardized rate ratios and 95% confidence intervals for the periods 1986-1990 and 1991-1995 were compared to assess geographical variations in risk. To investigate changes in the magnitude of most recent trends, regression models fitted to the latest available 10-year period (1988-1997) were compared with trends in the previous decade. Fitted rates in younger (40-64) and older adults (65-74) in the most recent period were also compared. RESULTS: There was a great deal of geographical variation in the risk of @entity2615 , annual rates ranging from around 8 per 100,000 in Scotland, England and The Netherlands, to lower than 1 per 100,000 in Spain (0.96), Estonia (0.85), Poland (0.85) and Yugoslavia, Vojvodina (0.56) among @entity1 . The rank of the rates for @entity1 was similar to that observed for @entity1 , although rates were considerably lower. Between 1978 and 1987, rates in @entity1 significantly increased in all countries (excepting Denmark). In the following 10 years, there was a deceleration in trend, and a significant increase was detectable only in England and France. In addition, the magnitude of recent trends in younger @entity1 was generally lower than those estimated for older @entity1 , in both national and regional cancer registry settings. CONCLUSIONS: While @entity2615 incidence rates are still rising in Europe, a deceleration has started in some countries. A decrease may begin in the next few years in certain European populations considering the deceleration of observed trends in @entity2615 and @entity1355 exposure, as well as the recent ban on its use.
